Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 3

Functional Restoration for Chronic Low Back Pain: Medico-economic Impact

NCT07472374 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2026-03-10
Last updated
2026-03-16

Condition(s) studied

Nonspecific Chronic Low Back Pain With Work Disability

Investigational drug(s) / intervention(s)

functional restorationnon-intensive rehabilitation

functional restoration: The functional restoration program will be carried out in investigation centers, in day hospitals, five days a week for four to five weeks, for a total of 110 hours ± 10. It will involve physicians specializing in physical medicine and rehabilitation or rheumatologists, and various medical rehabilitation assistants for physical therapy, occupational therapy, therapeutic education, and social assistance. Occupational physician and, where applicable, medical advisor, for each patient will also be involved. The program is organized into modules provided in group or individual sessions. Patients will receive daily medical follow-up, which will contribute to psychological support, allow for the adjustment of pain medication, and, if necessary, the adaptation of the program. Patients will be referred, as needed, to a psychologist or psychiatrist for joint care. A predetermined step-by-step progression will be proposed and established based on initial abilities for physical interventions.

non-intensive rehabilitation: Treatment for the comparator group will involve: a doctor specializing in physical medicine and rehabilitation or rheumatology (two consultations), physical therapists (12 half-hour sessions), social workers (one visit), occupational physicians (one consultation), and, as needed, psychiatrists and psychologists. Patients will also attend two educational sessions. The educational sessions will take place at the investigation centers. They will be conducted by non-medical staff. The topics covered will include inappropriate fears and beliefs, physical activity, neurophysiology and pain management, and coping strategies. The physical therapy sessions will be conducted in outpatient setting. The prescription for physical therapy will specify 12 sessions over 5 weeks, devoted to supervised practice of mobilization, stretching, and muscle strengthening techniques, as well as learning self-rehabilitation.

Study summary

The hypothesis is that functional restoration is not only effective in term of activity limitation, but also efficient, in regard to its impact on this criterion, the use of healthcare services, return to work and job retention, in the context of chronic low back pain with occupational disability.

The main objective is the medico-economic evaluation of a functional restoration program for chronic low back pain, in order to determine its efficiency using a differential cost-utility approach from an insurance perspective at 24 months after inclusion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
69 Years
Healthy volunteers
No
Inclusion Criteria: * Low back pain for at least 3 months * Low back pain with an intensity greater than or equal to 40/100 on a visual analog scale * Low back pain with a mechanical pattern (reduced by rest) * Low back pain on mobilization or palpation of the lumbar spine * Standard X-ray or MRI of the lumbar spine taken at the same time as the low back pain, showing normal or degenerative (arthritic) changes in the lumbar spine * Patient on sick leave due to low back pain for at least 3 months and less than 2 years * Patient who speaks and writes French * Patient with social security coverage Exclusion Criteria: * Low back pain of inflammatory, infectious, tumorous, or fracture origin * Radiculalgia in a lower limb greater than 40/100 * Radiculalgia in a lower limb with neurological complications (motor function less than or equal to 3/5 or cauda equina syndrome) * Cortisone injection into the lumbar spine in the previous month * Lumbar spine surgery in the previous 6 months * Heart or respiratory failure * Psychiatric condition preventing assessment of low back pain * Pregnancy * Refusal to participate in the study * Individuals benefiting from judicial protection measures

Primary outcome measure(s)

  • Incremental cost per quality-adjusted life year (QALY) — At 24 months after randomization
    Incremental cost per quality-adjusted life year (QALY) at 24 months after inclusion, established using the EuroQol 5 Dimensions (EQ-5D) questionnaire and resource utilization costs. Resource utilization costs correspond to healthcare costs and compensation for occupational disability.

Trial sites (1)

FacilityCityRegionStatus
Department of Physical Medicine and Rehabilitation; Lariboisière - Fernand Widal Hospital. Paris Île-de-France Region
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07472374 on ClinicalTrials.gov ↗ ← All trials in France